209809-34-7

Upstream product

• 141580-78-1 2-allyl-4-(4-fluorophenoxy)phenol 
• 371-41-5 4-Fluorophenol 
• 1524-19-2 4-(4-fluorophenoxy)phenol 
• 459-57-4 4-fluorobenzaldehyde 
• 137736-06-2 4-(4-fluorophenoxy)benzaldehyde 
• 141580-77-0 4-(4-fluorophenoxy)phenyl allyl ether 

Downstream Products

• 592508-55-9 (4-{3-[4-(4-fluoro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 
• 606966-69-2 (3-{3-[4-(4-fluoro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-hydroxy-acetic acid methyl ester 
• 228577-38-6 5-[4-(3-(2-propyl-4-(4'-fluorophenoxy)phenoxy)propoxy)phenyl]-2,4-thiazolidinedione 
• 656235-26-6 5-(4-{3-[4-(4-fluoro-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-2-imino-thiazolidin-4-one 

Relevant academic research and scientific papers

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.

Antidiabetic agents

The instant invention is concerned with aryl and heteroaryl oxyacetic acid type compounds which are useful antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and related diseases and for lowering triglyceride levels are also disclosed.